InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,702.55
(
-0.19%
)
US TECH 100
19,287.60
(
-0.24%
)
Dow Jones
42,063.36
(
0.09%
)
Brent Oil
74.14
(
0.00%
)
Bitcoin
63,060.75
(
-0.23%
)
Post# of 7747
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

whytestocks

Send PM Follow Ignore
Followers 130
Posts 14996
Boards Moderated 1
Alias Born 06/04/2018

whytestocks

Re: None

Tuesday, 10/13/2020 10:45:30 PM

Tuesday, October 13, 2020 10:45:30 PM

Post# of 7747
Just In: $CYTR CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio's Expanded Phase 2 Study of Pancreatic Cancer Treatment

Third-Line Cohort Added to Phase 2 Pancreatic Cancer Trial for Combination Immunotherapy That Includes Aldoxorubicin, ImmunityBio’s N-803 and NantKwest’s PD-L1 t-haNK Three Trial Sites in California and South Dakota Will Initially Enroll 298 Patients Across...

Find out more CYTR - CytRx Highlights Use of Licensed Drug Aldoxorubicin in ImmunityBio's Expanded Phase 2 Study of Pancreatic Cancer Treatment
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up